Literature DB >> 6264023

Hepatitis A antibody in Israel Defence Forces recruits.

J D Kark, S Bar-Shani.   

Abstract

Sera drawn from a sample of 1,147 military inductees, representative of the conscript population entering service in the Israel Defence Forces (IDF), in 1977, were examined by radioimmunoassay for hepatitis A virus (HAV) antibody. The prevalence of HAV antibody is considerably higher in males of Eastern origin (84.4%) than of Western origins (39.7%) and in females of Eastern origin (79.9%) as compared with those of Western origin (30.3%). The difference between males and females is not statistically significant when level of education is controlled. An inverse association between years of schooling and HAV antibodies is evident both for males and females, but is stronger in Westerners than Easterners. These findings have implications for HAV prevention in the IDF.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6264023     DOI: 10.1002/jmv.1890060409

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  6 in total

1.  Cost-benefit analysis of a nationwide neonatal inoculation programme against hepatitis B in an area of intermediate endemicity.

Authors:  G M Ginsberg; D Shouval
Journal:  J Epidemiol Community Health       Date:  1992-12       Impact factor: 3.710

2.  Decline of hepatitis A antibodies during the first 7 months of life in full-term and preterm infants.

Authors:  N Linder; Y Karetnyi; Y Gidony; R Dagan; G Ohel; E Levin; E Mendelson; A Barzilai
Journal:  Infection       Date:  1999 Mar-Apr       Impact factor: 3.553

3.  Sociodemographic correlates of neutralizing poliovirus and hepatitis A virus antibodies as markers of different modes of acquiring immunity.

Authors:  M S Green; D Cohen; R Slepon; R Handsher; Y Zaaide; L Rannon; Y Danon
Journal:  Am J Public Health       Date:  1990-10       Impact factor: 9.308

4.  Serological hepatitis A virus infections and ratio of clinical to serological infections in a controlled trial of pre-exposure prophylaxis with immune serum globulin.

Authors:  J D Kark; S Bar-Shany; S Shor; L Merlinski; E Nili
Journal:  J Epidemiol Community Health       Date:  1985-06       Impact factor: 3.710

5.  The three-year incidence of non-B viral hepatitis morbidity in a controlled trial of pre-exposure immune serum globulin prophylaxis.

Authors:  J D Kark; E Witztum; H Mazkin; E Nili; Y L Danon
Journal:  Infection       Date:  1984 Jul-Aug       Impact factor: 3.553

6.  Cost-benefit analysis of a nationwide inoculation programme against viral hepatitis B in an area of intermediate endemicity.

Authors:  G M Ginsberg; S Berger; D Shouval
Journal:  Bull World Health Organ       Date:  1992       Impact factor: 9.408

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.